Further evaluation of ICI-response biomarkers in addition to PD-L1 expression, such as tumor microsatellite instability, tumor mutation burden, and circulating DNA, will help to determine which patients may benefit the most from this approach. This evidence concerns the gene CD274 and neoplasm.